|
US2010247482A1
|
|
Tight junction modulator peptides for enhanced mucosal delivery of therapeutic compounds
|
|
US2008299659A1
|
|
Nucleic acid compounds for inhibiting apob gene expression and uses thereof
|
|
US2008293136A1
|
|
Nucleic acid compounds for inhibiting akt gene expression and uses thereof
|
|
CA2666657A1
|
|
Nicked or gapped nucleic acid molecules and uses thereof
|
|
CN101677948A
|
|
Intranasal carbetocin formulations and the autistic method of treatment
|
|
EP2051965A2
|
|
Dicer substrate rna peptide conjugates and methods for rna therapeutics
|
|
US2008119408A1
|
|
Pth formulations for intranasal delivery
|
|
US2008029084A1
|
|
Device for improved peptide delivery
|
|
US2007293449A1
|
|
Compositions and methods for delivery of double-stranded rna
|
|
US2007269892A1
|
|
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
|
US2007281900A1
|
|
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
|
|
US2009325860A1
|
|
Compositions for intranasal delivery of human insulin and uses thereof
|
|
US2007213293A1
|
|
Rnai therapeutic for respiratory virus infection
|
|
US2007275923A1
|
|
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
|
US2007276134A1
|
|
Compositions and methods for complexes of nucleic acids and organic cations
|
|
US2007293657A1
|
|
Complexes and methods of forming complexes of ribonucleic acids and peptides
|
|
US2007172430A1
|
|
Dry powder compositions for rna influenza therapeutics
|
|
WO2007146448A1
|
|
Pharmaceutical formulations of glp-1 derivatives
|
|
US2007185035A1
|
|
Enhanced mucosal administration of neuroprotective peptides
|
|
US2007232537A1
|
|
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
